220 related articles for article (PubMed ID: 32333920)
1. Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4.
Naso JR; Churg A
Hum Pathol; 2020 Jun; 100():10-14. PubMed ID: 32333920
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
Ordóñez NG
Hum Pathol; 2004 Jun; 35(6):697-710. PubMed ID: 15188136
[TBL] [Abstract][Full Text] [Related]
3. The utility of claudin-4 versus MOC-31 and Ber-EP4 in the diagnosis of metastatic carcinoma in cytology specimens.
Najjar S; Gan Q; Stewart J; Sneige N
Cancer Cytopathol; 2023 Apr; 131(4):245-253. PubMed ID: 36522809
[TBL] [Abstract][Full Text] [Related]
4. HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma.
Naso JR; Tsuji S; Churg A
Am J Surg Pathol; 2020 Aug; 44(8):1143-1148. PubMed ID: 32205484
[TBL] [Abstract][Full Text] [Related]
5. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236
[TBL] [Abstract][Full Text] [Related]
6. Hypothesis: HEG1 and claudin-4 staining will allow a diagnosis of epithelioid and biphasic mesothelioma versus non-small-cell lung carcinoma with only two stains in most cases.
Churg A; Naso JR
Histopathology; 2023 Feb; 82(3):385-392. PubMed ID: 36008876
[TBL] [Abstract][Full Text] [Related]
7. Claudin-4 immunohistochemistry is a useful pan-carcinoma marker for serous effusion specimens.
Vojtek M; Walsh MD; Papadimos DJ; Shield PW
Cytopathology; 2019 Nov; 30(6):614-619. PubMed ID: 31390089
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study.
Ordóñez NG
Mod Pathol; 2006 Jan; 19(1):34-48. PubMed ID: 16056246
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study.
Ordóñez NG
Mod Pathol; 2006 Mar; 19(3):417-28. PubMed ID: 16415794
[TBL] [Abstract][Full Text] [Related]
10. MOC-31 exhibits superior reactivity compared with Ber-EP4 in invasive lobular and ductal carcinoma of the breast: a tissue microarray study.
Pai RK; West RB
Appl Immunohistochem Mol Morphol; 2009 May; 17(3):202-6. PubMed ID: 19391212
[TBL] [Abstract][Full Text] [Related]
11. GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung.
Berg KB; Churg A
Am J Surg Pathol; 2017 Sep; 41(9):1221-1225. PubMed ID: 28614203
[TBL] [Abstract][Full Text] [Related]
12. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
[TBL] [Abstract][Full Text] [Related]
13. Immunocytochemical utility of claudin-4 versus those of Ber-EP4 and MOC-31 in effusion cytology.
Oda T; Ogata S; Kawaguchi S; Minabe S; Dokyu M; Takahashi H; Kumazawa F; Shimazaki H; Takano M; Hase K; Ozeki Y; Kanoh S; Nakanishi K
Diagn Cytopathol; 2016 Jun; 44(6):499-504. PubMed ID: 27015745
[TBL] [Abstract][Full Text] [Related]
14. Claudin-4 as a marker for distinguishing malignant mesothelioma from lung carcinoma and serous adenocarcinoma.
Ohta Y; Sasaki Y; Saito M; Kushima M; Takimoto M; Shiokawa A; Ota H
Int J Surg Pathol; 2013 Oct; 21(5):493-501. PubMed ID: 23775021
[TBL] [Abstract][Full Text] [Related]
15. Immunoreactivity for BER-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas.
Gaffey MJ; Mills SE; Swanson PE; Zarbo RJ; Shah AR; Wick MR
Am J Surg Pathol; 1992 Jun; 16(6):593-9. PubMed ID: 1599037
[TBL] [Abstract][Full Text] [Related]
16. Uroplakin-IIIb as a novel immunohistochemical marker for mesothelioma.
van Pel DM; Cheung S; Ionescu DN; Churg A
Hum Pathol; 2023 Nov; 141():64-68. PubMed ID: 37776956
[TBL] [Abstract][Full Text] [Related]
17. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.
Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y
Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712
[TBL] [Abstract][Full Text] [Related]
18. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
Ordóñez NG
Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of Metastatic Carcinoma Using Body Cavity Fluid Specimens: A Comparison of Diagnostic Panels.
Sridakhun N; Intarawichian P; Thanee M; Watcharadetwittaya S
Acta Cytol; 2023; 67(3):257-264. PubMed ID: 36513033
[TBL] [Abstract][Full Text] [Related]
20. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions.
Delahaye M; van der Ham F; van der Kwast TH
Diagn Cytopathol; 1997 Aug; 17(2):115-20. PubMed ID: 9258618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
